BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld
BioWorld
July 9, 2003
View Archived Issues
Killer Clots That Attack Heart, Brain Countered By Clot-Busting Drugs Linked To Red Blood Cells
Read More
XOMA Regains Full Rights To Neuprex As Baxter Pulls Out
Read More
AEterna To Raise C$35.6M Upon Entering Bought-Deal Agreement
Read More
Other News To Note
Read More
Amgen Files With FDA Seeking Approval Of Enbrel In Psoriasis
Amgen Inc.'s Enbrel could be the first TNF blocker to make it to market as a treatment for psoriasis, an inflammatory disease often mischaracterized as a disease of the skin. (BioWorld Today)
Read More
Genentech's Avastin Rights Outside U.S. Go To Roche
Read More